Kailera Therapeutics, Inc. KLRA
13.27 USD +0.06 (+0.45%)
Regular-session close
13.00 -0.27 -2.03%
After hours · Nov 13, 7:58 PM ET
12.78 Day range 13.62
10.00 52-week range 26.00
- YTD
- -48.96%
- 1 year
- -48.96%
News
globenewswire.com Kailera Therapeutics to Present at ObesityWeek 2026 Ribupatide injection Phase 3 KaiNETIC trial design presentations highlight its potential to address diverse needs across the obesity spectrum Real-world obesity management presentation highlights the…
benzinga.com Canaccord Genuity Initiates Coverage On Kailera Therapeutics with Buy Rating, Announces Price Target of $44 Canaccord Genuity analyst Edward Nash initiates coverage on Kailera Therapeutics (NASDAQ:KLRA) with a Buy rating and announces Price Target of $44.
benzinga.com Kailera Therapeutics Q3 EPS $(0.74) Beats $(1.02) Estimate Kailera Therapeutics (NASDAQ:KLRA) reported quarterly losses of $(0.74) per share which beat the analyst consensus estimate of $(1.02) by 27.45 percent.
benzinga.com Kailera Therapeutics Completes Enrollment In KaiNETIC Global Phase 3 Clinical Program; Topline Data Now Expected In Mid-2028 - Ribupatide injection (KAI-9531) aims to address critical need for greater weight loss, especially for people living with a BMI of 35 kg/m² or higher- Topline data now expected in mid-2028WALTHAM,…
benzinga.com Jim Cramer Recommends Buying This Energy Stock, Calling It ‘Very Inexpensive’ Jim Cramer favors Texas Pacific Land, calls Kailera his speculative pick, and criticizes P&G, Ondas and Tractor Supply.- benzinga.com Kailera Therapeutics Q2 EPS $(1.09) Misses $(0.74) Estimate Kailera Therapeutics (NASDAQ:KLRA) reported quarterly losses of $(1.09) per share which missed the analyst consensus estimate of $(0.74) by 47.3 percent.
benzinga.com Why Is Kailera Therapeutics Stock Falling Tuesday? Kailera Therapeutics oral GLP-1 meets Phase 3 targets for obesity and diabetes. KLRA stock falls 9% on reported GI side effects.- benzinga.com Kailera Therapeutics Announces Topline Data From Two Additional Phase 3 Clinical Trials Of Oral Small Molecule GLP-1 Receptor Agonist HRS-7535 Conducted By Hengrui Pharma In China In Phase 3 trial in obesity/overweight in China, HRS-7535 achieved a mean weight loss of up to 10.9% at Week 44 and a mean weight loss of up to 11.1% at Week 50 Kailera currently conducting global…
benzinga.com Kailera Therapeutics Q1 EPS $(3.65) Misses $(0.68) Estimate as R&D Spend Jumps to $70.9M Kailera Therapeutics (NASDAQ:KLRA) reported quarterly losses of $(3.65) per share which missed the analyst consensus estimate of $(0.68) by 444.78 percent as R&D spend Jumps to $70.9M.
benzinga.com This Weight-Loss Drug Challenger Could Follow Eli Lilly's Playbook: Analyst William Blair gives Kailera Therapeutics ($KLRA) an Outperform rating. Learn why analysts see a competitive edge in their GLP-1 assets.
benzinga.com Hengrui Pharma, Kailera Therapeutics To Present Two Abstracts At 86th Scientific Sessions Of The American Diabetes Association Hengrui Pharma (Hengrui), a global pharmaceutical company focused on scientific and technological innovation, and Kailera Therapeutics, Inc. (Kailera), an advanced clinical-stage biotechnology…
benzinga.com Leerink Partners Initiates Coverage On Kailera Therapeutics with Outperform Rating, Announces Price Target of $36 Leerink Partners analyst David Risinger initiates coverage on Kailera Therapeutics (NASDAQ:KLRA) with a Outperform rating and announces Price Target of $36.- benzinga.com Jefferies Initiates Coverage On Kailera Therapeutics with Buy Rating, Announces Price Target of $48 Jefferies analyst Roger Song initiates coverage on Kailera Therapeutics (NASDAQ:KLRA) with a Buy rating and announces Price Target of $48.
- benzinga.com Evercore ISI Group Initiates Coverage On Kailera Therapeutics with Outperform Rating Evercore ISI Group analyst Umer Raffat initiates coverage on Kailera Therapeutics (NASDAQ:KLRA) with a Outperform rating.
benzinga.com This Southwest Gas Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday Analysts change outlook on top names. Check their ratings & price targets for AVEX, ALMR, TNDM, SWX, KLRA. See what they think of SWX stock.
benzinga.com JP Morgan Initiates Coverage On Kailera Therapeutics with Overweight Rating, Announces Price Target of $30 JP Morgan analyst Hardik Parikh initiates coverage on Kailera Therapeutics (NASDAQ:KLRA) with a Overweight rating and announces Price Target of $30.
benzinga.com Kailera Therapeutics' Strong IPO Validates "NewCo" Strategy 
benzinga.com Kailera Therapeutics Debut Marks Largest Biotech IPO Since 2021 Amid Weight Loss Race Kailera Therapeutics prices $625 million IPO, advances GLP-1 obesity pipeline as trial data highlights oral ribupatide weight loss results.